For example, the discovery of epidermal growth factor receptor (EGFR) mutations in lung cancer was prompted by the clinical observation that a subset of patients exhibited a major response when administered tyrosine kinase inhibitors in clinical trials [16–18]. This evidence concerns the gene EGFR and lung cancer.